Most wouldn't pay more than $2,500 for a personalized cancer test
Core finding
Most U.S. adults (69%) would not pay more than $2,500 for a highly reliable cancer test that comes with personalized treatment options, in a Verasight survey conducted Aug. 13-18, 2025.
About one-in-six (17%) would go as high as $5,000 and 6% as high as $10,000. A smaller tail would pay far more: 3% up to $20,000 and 5% more than $20,000 if necessary.
Topline distribution
Most wouldn't pay more than $2,500 for a personalized cancer test.
What is the highest price you are willing to pay for a 95% reliable cancer biomarker test which gives you personalized treatment options?
n = 1,000 · Aug 13–18, 2025 · MoE ±3.1%
Methodology
Full methodology →| Mode | Verasight panel recruited via random address-based sampling, random person-to-person text messaging, and dynamic online targeting |
|---|---|
| Population | United States adults |
| Field dates | Aug 13–18, 2025 |
| Base (unweighted) | 1,000 |
| Margin of error | ±3.1% |
| Module | Verasight JSM Omnibus Survey |
| Sponsor | Verasight |
| Weight variable | weight |
| Weighting targets | age, race/ethnicity, sex, income, education, region, metropolitan status |
Sources
- reports.verasight.io/r/jsm-2025
What is the highest price you are willing to pay for a 95% reliable cancer biomarker test which gives you personalized treatment options?
Cite this question
Verasight JSM Omnibus Survey, fielded August 13-18, 2025, N=1,000 United States adults, +/- 3.1%.